Feeds:
Posts
Comments

Second heart sound in TOF is often single and loud . It is often  best heard in left 2nd intercostal space as well as on right 2nd  space.

This is primarily due

  1. Presence of  pulmonary stenosis  and  resultant reduced pulmonary blood flow makes P2 soft or absent .Hence  A2 becomes loud by default.
  2. In tune with any  cono -truncal anomaly  , aortic root  is  anteriorly  malposed  in TOF. This brings the aorta  closer to chest wall  (Nullifying the  aquastic insulation  of main  pulmonary trunk  ) and results in a  booming aortic  second heart sound.
  3. Increased flow across  aortic valve . In cyanotic heart disease with reduced pulmonary blood flow aortic flow is augmented and may even result in dilatation of aorta . A large aorta with increased flow is perfect setting  for  generating a loud A2  . It  is common to hear a  aortic ejection click as well in these situations .

When you hear a single  second heart sound at  the base  of heart  , how do you recognise it to be   A2  or P2 ?

Will be answered shortly.

Gynecologists  do have  interactions with cardiologists  frequently  in their day to day practice.In fact ,  in any big hospitals cardiologist consult  invariably happen every day . In our institute  fellows visit the maternity ward almost daily to give opinion   about a cardiac issues .  These are mainly emergencies like  breathless   rheumatic heart  patient  in labor , A DVT to R/O pulmonary embolism,  women  with prosthetic valve waiting for delivery, and a  women with LV dysfunction posted for hysterectomy  etc.

While it is common  for  our  Gynec colleagues to call us in  emergencies ,   and we do have a cardiac clinic every week ,  it is rare to discuss broad based practice  issues. There is little inter departmental  brain storming sessions.

Here is an excellent initiative from  European union where they have  created consensus document for reducing  cardiac risk  in peri menopausal  women.(http://eurheartj.oxfordjournals.org/content/28/16/2028.full.pdf+html)

The beauty of this document lies in the succinct practice points written in every  page .

In India , even though premier bodies like cardiological  society of  India  exits it rarely  considers bringing about such guidelines  in collaboration with other scientific bodies . ( To be  more precise  . . .they  do not have their own guidelines either ! )

I believe , FOGSI  (Federation of Obstetrics and gynecologists society of India ) is doing a much better job and they have created exclusive guidelines in O & G.


Q : Beta blockers reduce  blood pressure mainly through

  1. Reduction in Heart rate
  2. Reduction in cardiac output
  3. Negative Inotropic action
  4. Vascular sensitization to circulating catecholamines
  5. Blocks  Renin secretion and  reduce vascular tone.

Answer : 5  (May be  4 as well !)

Our understanding of beta blocker’s  action  in SHT has changed considerably over the years .The  negative inotropic action on the myocardium  attributed for BP reduction ,  is no longer considered  important . Now we know , beta blockers can  reduce peripheral vascular resistance significantly.(There were days , we presumed  the opposite to be  true ,  ie when beta blockers are blocked , alpha action will overshoot to cause excess vascular resistance ! ) This  is more of  perceived fear.  This concept was never proved convincingly even in the  dreaded  Prinzmetal  angina* where beta blockers are  relatively contraindicated for fear of  aggravating vasospasm.

*Note : This is may  still be valid in selected few  who  show a  tendency for  Raynaud  phenomenon especially in peripheral vascular  system.


Additional  factors   influencing  beta blockers in SHT

  • Suppression  of  central adrenergic drive  ,  modulation of   brain stem vasomotor centre  are aslo considered vital . This action is linearly related to the ability of beta blockers to cross the blood brain barrier which is more with lipophilic drugs like metoprolol.
  • The role of beta blocker in isolated systolic hypertension in elderly  is unique.Here it reduces the myocardial dp/dt (ie contractility )  and hence help them prevent  systolic spikes of pressure and the resultant  stroke.
  • The newer  vasodilating beta blockers  like Nebivolol, (Nitric oxide mediated ?)  and Carvidilol may have additional advantage in controlling BP.
  • It needs to be appreciated , beta blockers combine well with  diuretics like  hydrochlorthaizide  .This  makes it easier to control severe forms of HT  especially volume dependent ones in  both young and elderly. (SHEP trial )

Final message

The modification of vascular response to catecholamines  is  the single most important mechanism of reduction of blood pressure.

This may be a direct consequence  of  1.  Blockade of  vascular  adrenergic receptors . 2  Indirectly  through suppression of  Rennin secretion.

Instent restenosis is a  common problem.

Diffuse long segment instent restenosis is somewhat rare.

We  encountered one such patient who had diffuse instent restenosis of RCA.

ISR is ssupposed to be rare in DES, but here ISR occured with a Cypher stent  one year following implantation

He presented with angina which  was relieved  by plain baloon angioplasty.

 link to a  related article in  this  site  regarding the mangementof ISR.

We know primary PCI is a race against time  both for the  patient  and his  physician.

What is the upper limit for this unique race where the stakes  are high   and it involves  human lives  and  big  corporate  warfares  ?

  1. 6 hours
  2. 12 hours
  3. 24 hours
  4. 36 hours
  5. 54 hours
  6. Time does not matter . You can do a PCI as late as possible as long as  patient has sufficient insurance coverage and we have the expertise

Answer : 2 

Please note there is  only one exception  . Cardiogenic  shock has been given a extended  lease of time window (Which can be technically up to  54 hours ) . PCI can be performed   if the onset of shock  is   within 36 hours  of STEMI  and to be performed within  18 hours after the onset ! )

* Even though we  have a  well set criteria for re-perfusion which bans primary PCI to be performed after 12 hours , cardiologists have enough technicalities to overcome this hurdle and keep doing the futile pPCI well after 12hours.

How they are   able to indulge in these futilities   without  any ethical issue ?

The answer  is very simple. Instead of calling it as primary PCI they refer to it as delayed PCI or rescue PCI !  Strict time specific guidelines are only for primary PCI . By changing the terminologies they   make a mockery of the concept of time window which  is vital for any intervention for STEMI !

Success of primary PCI is defined by  different yardsticks  by  different  cardiologists  , in different  institutions !  But , for the patient and his family,  getting  discharged   alive with out symptoms is a huge  success !

They  do not bother  even if they are charged  Rs 3-4 lakh for their stay ,  as they  believe  surviving  a heart attack  is a God’s grace   rendered thorough the hands of  the doctor.

But we know  the real success lies elsewhere. Cardiologist’s   perception of   success of  pPCI   should be based on scientific concepts. Unfortunately many  physicians  continue to  think like  their patients  . This  tendency to get self gratification  with a patient’s  frame of  mind is  common  and  needs  introspection .

This is esepcailly  true for primary PCI . It came with big fanfare  a decade ago . Soon ,many cardiologists developed  a habit  of criticizing   the  practice thrombolysis for STEMI .If primary PCI is such a superior modality  every patient   should be prevented from significant  myocardial damage following  STEMI .

Primary PCI  may be the the most logical method  still , for reverting the STEMI process  . But “A properly performed  primary PCI  as a  concept ” lies  mainly  on paper ,  not  been  replicated in real world for various reasons.

Please remember , a successful primary PCI

  • Is  not restoring TIMI 3 flow  in IRA
  • Is not relieving  the  angina
  • Is not discharging a  patient in stable condition

Even if  . . .  we accomplish each one of the above  . . .   if   the patient  carries  home  anything  equal  to ,  or more than moderate LV dysfunction ,  primary PCI  has  deemed to have failed.

Final message

What is the reality  check ?  In one  of  the  preliminary analysis   out of 20 randomly selected  patients  who have undergone STEMI*   within 12 hours  , significant LV dysfunction  was present in  12  patients making it pPCI only 40 % successful   in real world  .( Which  would struggle to beat the outcome of  promptly administered fibrinolysis )

* Primary PCI done in state of the art institutes .

“STEMI is Acute MI” , and   “Acute MI is STEMI”  !   This is  how we  have been taught over the years.

But   STEMI can present in any one of  the following  odd ways

1. Posterior MI with ST depression in V1 to V3 ( Manytimes mistaken for unstable angina , and reperfusion not considered !)

2.Only with tall T waves (TEMI)

3. Left bundle branch block

4. Present as ventricular tachycardia. Untill VT  it is reverted ST elevation  will not  manifest.

5. When a  STEMI presents with  complete heart block   ST elevation may not manifest.

6.Atypical ECGs and subtle ECG changes are especially common in elderly, diabetic and in patients with LVH.

7. Finally,  it is often quoted in text books  acute MI occurs with normal ECG in up to 10 % . This is  a  high estimate .We belive acute MI with normal ECG is very rare presentation < 1% . That too in the very early stages of evolving MI.

As of now  only condition No  1 and 3 are approved  for  thrombolysis or PCI.  The unfortunate few who fall in other categories will continue to lose their muscle in the golden hour without any intervention  as the guidelines has not addressed these issues.

Pulmonary hypertension (PH)is a very common clinical problem in cardiology.The classification of PH  has been little complex. Now we have a fairly clear scheme formulated in 2008 in a small beach side county of  California called Dana point .

I have tried to simplify it without affecting the core

Click on the image if  slide is not displaying

Category 1 is again divided into 5 categories

1.1 /1.2/1.3/1.4/1.5

Other categories( Category 2 to 5)

* Note there is a special category called 1 ‘ for pulmonary veno-occlusive disease .This should be distinguished from CTEPH

Summary

Remember  99 %  all  pulmonary hypertension will be constituted by the following  seven entities .

Idiopathic PAH  1.1

Familial PAH       1.2

Connective tissue disease 1.4.1

Congenital heart disease  1.4.4

Left sided valvular /Myocardial heart disease 2.3.3

Secondary to  COPD  3.1

CTEPH   4

In India  (probably worldwide ) the commonest  cause for  PH is  2.3.3

The updated pulmonary hypertension  classification is available here

Before answering the above question ,  there need to be a correction to the question itself . PDA is persistence of ductus arteriosus . In pulmonary atresia ductus itself is not formed .So  the question should  ideally be  Why  ductus  is absent in pulmonary atresia  with VSD  !

Ductus  is formed from the dorsal portion of left 6th arch  .The sixth arch also gives raise to  right and left pulmonary artery.This can happen only if everything from aortic arch and pulmonary artery development is normal

Ductus  has to connect aorta with left pulmonary artery  , when pulmonary artery itself is  poorly developed or not developed   how can the  ductus  connect to  LPA ?

Pulmonary atresia is essentially a defect in the development of pulmonary arterial tree (Please note pulmonary valve and  MPA  is formed  from different  structures in different times and it  would  get  docked  with developing LPA,RPA  and  subsequently to the rest of the  pulmonary tree .)

In fact , one of the terminologies used for pulmonary atresia with VSD  is ,  total anomalous pulmonary arterial connection(TAPAC)  .In fetal    life,   blood flow in ductus is from RV  to  pulmonary artery  and then to  descending aorta  through the  ductus . When RV is disconnected with pulmonary artery( Rather there is no pulmonary artery )  ductus can not be  formed  for  both anatomical and physiological reasons . Some consider the  left 6th arch  in these patients  would become  a poorly   identifiable  minor Aorto pulmonary channel .

A Link to  3D vedio  of aortopulmonary collateral

Embryology of major aorto pulmonary collaterals.

  • The lung perfusion in patients with pulmonary atresia is important only after birth,  as fetal  lung is largely non functional.
  • In patients with pulmonary atresia with  intact IVS this becomes  critical and  usually death ensues unless intervened.
  • If VSD is present it allows the baby to survive as the  lung gets perfused by major or minor aortopulmonary collaterals.
  • These collaterals can range between extensive and   sparse.  Hence the  symptoms can  also vary from volume overload  /cardiac failure to  severe oiligemia  and recurrent  hypoxic spells.*

MAPCOS ,  if present can connect directly the aorta  to  hilar pulmonary artery or indirectly  from the branches of  aorta (subclavian /LIMA/RIMA etc) . These arteries  supply  with or without  a central confluence . It may enter the lung through the hilum or  away from hilum .The MAPCOS can be located anywhere from the arch of aorta to descending thoracic aorta.It is very rare in the ascending Aorta .

There is also  strong argument for MAPCOS are  nothing but dilated bronchial arteries.(Link to Full text )

*The  natural history  directly depends  on  extent of aorto pulmonary collaterals and its anatomical patency .

Final message

Embryologically   both  the  major  arteries of thorax  Aorta and Pulmonary artery have  the  same parent structure namely the dorsal aorta and its six  arches.Hence there  is no surprise  ,  when these embryological  divisions and fusions   goes awry ,   pulmonary artery fails to get  carved out from  the dorsal aorta  in the normal fashion .The randomly formed pulmonary  arteries continue  to have link  with   the parent -dorsal aorta .These are manifested in various ways as major aorto pulmonary collaterals .

(It is to be noted  in pulmonary atresia  , VSD is an offshoot developmental defect  . Embryologically  VSD   is not linked to the primary defect of pulmonary artery development . This is the reason many would consider   PA with VSD as a  distinct entity with that of TOF (Which is a cono truncal anomaly) This also explains the lack of MAPCOS in true TOF .

When know   statins have  revolutionised  the management of  coronary artery disease , why  we  hesitate  to  say   the same thing    for  cerebro vascular disease ?

Is it because

       Atherosclerosis is different in  cerebrovascular disease   than coronary artery  disease

 or  Blood pressure control  becomes more important in preventing stroke than lipids?

Unlike  MI ,  Cerebro vascular system   have   variety of insults.

  • Embolic stroke
  • Thrombotic stroke
  • Ischemic stroke
  • Hemorrhagic stroke
  • Low flow – Water shed infarcts

Hemorrhagic , embolic and low flow mediated  myocardial infarction are very rare and  denova hemorrhagic MI is non existent.This is due  to  the fact ,  coronary autoregulation is  vastly different from cerebral vessels. Carotid plaque stabilisation  is a  major mechanism by which statins can prevent stroke . Still , statin  therapy( however aggressive)  has less impact  in the incidence  of stroke than MI.

This meta analysis claims statin to be very  effective  in prevention of ischemic stroke.

We have observed  ,simple statin administration without concomitant BP reduction has absolutely no effect on stroke prevention,   while  in  coronary  prevention even if the blood pressure optimisation is less than the desired levels,  significant number of  MI are still  prevented.

http://www.ncbi.nlm.nih.gov/pubmed/18187070

 The  SPARCL  trial  was big boost  for   statin   industry  in widening the Indication  for stroke prevention

 

Final message

Does statins remain a suspect in stroke prevention ?

If we  accept the  saying   ” Data won’t lie ” . .  . the suspicion  about  statins  is  a myth.

High dose Atorvastatin 80mg /day should be prescribed for every one with at high risk for ischemic stroke .